Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.
Walter J StorkusDeena MaurerYan LinFei DingAnamika BoseDevin LoweAmy RoseMelissa DeMarkLilit KarapetyanJennifer L TaylorManoj ChelvanambiRonald J FecekJessica N FildermanTimothy J LooneyLauren MillerElizabeth LinchGeoffrey M LowmanPawel KalinskiLisa H ButterfieldAhmad A TarhiniHussein A TawbiJohn M KirkwoodPublished in: Journal for immunotherapy of cancer (2022)
NCT01876212.